161869-03-0Relevant articles and documents
HIV PROTEASE INHIBITORS
-
Page/Page column 43, (2013/05/21)
Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which
Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors
Jones, Kristen L.G.,Holloway, M. Katharine,Su, Hua-Poo,Carroll, Steven S.,Burlein, Christine,Touch, Sinoeun,DiStefano, Daniel J.,Sanchez, Rosa I.,Williams, Theresa M.,Vacca, Joseph P.,Coburn, Craig A.
body text, p. 4065 - 4068 (2010/09/04)
A series of HIV-1 protease inhibitors containing an epsilon substituted lysinol backbone was synthesized. Two novel synthetic routes using N-boc-l-glutamic acid alpha-benzyl ester and 2,6-diaminopimelic acid were developed. Incorporation of this epsilon s
Lysine sulfonamides as novel HIV-protease inhibitors: Nε-Acyl aromatic α-amino acids
Stranix, Brent R.,Lavallee, Jean-Francois,Sevigny, Guy,Yelle, Jocelyn,Perron, Valerie,LeBerre, Nicholas,Herbart, Dominik,Wu, Jinzi J.
, p. 3459 - 3462 (2007/10/03)
A series of lysine sulfonamide analogues bearing Nε-acyl aromatic amino acids were synthesized using an efficient synthetic route. Evaluation of these novel protease inhibitors revealed compounds with high potency against wild-type and multiple-protease inhibitor-resistant HIV viruses.